Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
- PMID: 14615107
- DOI: 10.1016/s0140-6736(03)14739-3
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
Abstract
Background: The benefits of reducing blood pressure on the risks of major cardiovascular disease are well established, but uncertainty remains about the comparative effects of different blood-pressure-lowering regimens. We aimed to estimate effects of strategies based on different drug classes (angiotensin-converting-enzyme [ACE] inhibitors, calcium antagonists, angiotensin-receptor blockers [ARBs], and diuretics or beta blockers) or those targeting different blood pressure goals, on the risks of major cardiovascular events and death.
Methods: We did seven sets of prospectively-designed overviews with data from 29 randomised trials (n=162341). The trial eligibility criteria, primary outcomes, and main hypotheses were specified before the result of any contributing trial was known.
Findings: In placebo-controlled trials the relative risks of total major cardiovascular events were reduced by regimens based on ACE inhibitors (22%; 95% CI 17-27) or calcium antagonists (18%; 5-29). Greater risk reductions were produced by regimens that targeted lower blood pressure goals (15%; 5-24). ARB-based regimens reduced the risks of total major cardiovascular events (10%; 4-17) compared with control regimens. There were no significant differences in total major cardiovascular events between regimens based on ACE inhibitors, calcium antagonists, or diuretics or beta blockers, although ACE-inhibitor-based regimens reduced blood pressure less. There was evidence of some differences between active regimens in their effects on cause-specific outcomes. For every outcome other than heart failure, the difference between randomised groups in achieved blood pressure reduction was directly related to the observed difference in risk.
Interpretation: Treatment with any commonly-used regimen reduces the risk of total major cardiovascular events, and larger reductions in blood pressure produce larger reductions in risk.
Comment in
-
Effects of different blood-pressure-lowering regimens on major cardiac events.Lancet. 2004 Jan 24;363(9405):331; author reply 331-2. doi: 10.1016/S0140-6736(03)15403-7. Lancet. 2004. PMID: 14751718 No abstract available.
-
Effects of different blood-pressure-lowering regimens on major cardiac events.Lancet. 2004 Jan 24;363(9405):332. doi: 10.1016/S0140-6736(03)15405-0. Lancet. 2004. PMID: 14751721 No abstract available.
-
Review: commonly used antihypertensive therapies and targeted blood pressure-lowering regimens reduce cardiovascular events.ACP J Club. 2004 May-Jun;140(3):72. ACP J Club. 2004. PMID: 15122835 No abstract available.
Similar articles
-
Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.J Hypertens. 2015 Feb;33(2):195-211. doi: 10.1097/HJH.0000000000000447. J Hypertens. 2015. PMID: 25485720 Review.
-
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.Lancet. 2000 Dec 9;356(9246):1955-64. doi: 10.1016/s0140-6736(00)03307-9. Lancet. 2000. PMID: 11130523
-
Effects of different blood-pressure-lowering regimens on major cardiac events.Lancet. 2004 Jan 24;363(9405):331; author reply 331-2. doi: 10.1016/S0140-6736(03)15403-7. Lancet. 2004. PMID: 14751718 No abstract available.
-
Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis.J Hypertens. 2018 Aug;36(8):1637-1647. doi: 10.1097/HJH.0000000000001777. J Hypertens. 2018. PMID: 29847487 Review.
-
Association between cardiovascular outcomes and antihypertensive drug treatment in older women.JAMA. 2004 Dec 15;292(23):2849-59. doi: 10.1001/jama.292.23.2849. JAMA. 2004. PMID: 15598916
Cited by
-
Diabetes and the risk of heart failure.Heart Fail Clin. 2012 Jan;8(1):125-33. doi: 10.1016/j.hfc.2011.08.008. Epub 2011 Oct 13. Heart Fail Clin. 2012. PMID: 22108732 Free PMC article. Review.
-
Cost-effectiveness analysis of integrating screening and treatment of selected non-communicable diseases into HIV/AIDS treatment in Uganda.J Int AIDS Soc. 2020 Jun;23 Suppl 1(Suppl 1):e25507. doi: 10.1002/jia2.25507. J Int AIDS Soc. 2020. PMID: 32562364 Free PMC article.
-
Dihydropiridinic Calcium-Channel Antagonists in the 2007 ESH/ESC Hypertension Guidelines.High Blood Press Cardiovasc Prev. 2008 Apr;15(2):85-90. doi: 10.2165/00151642-200815020-00007. Epub 2013 Jan 3. High Blood Press Cardiovasc Prev. 2008. PMID: 23334876
-
Prevention of coronary artery disease: recent advances in the management of hypertension.Curr Atheroscler Rep. 2013 Mar;15(3):311. doi: 10.1007/s11883-013-0311-2. Curr Atheroscler Rep. 2013. PMID: 23338675 Review.
-
Antihypertensive drugs and coronary artery disease : evidence from controlled trials.High Blood Press Cardiovasc Prev. 2005 Sep;12(3):119-24. doi: 10.2165/00151642-200512030-00002. High Blood Press Cardiovasc Prev. 2005. PMID: 23361602
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous